Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 6 (1), 15

The Production Processes and Biological Effects of Intravenous Immunoglobulin

Affiliations
Review

The Production Processes and Biological Effects of Intravenous Immunoglobulin

Ana Filipa Barahona Afonso et al. Biomolecules.

Abstract

Immunoglobulin is a highly diverse autologous molecule able to influence immunity in different physiological and diseased situations. Its effect may be visible both in terms of development and function of B and T lymphocytes. Polyclonal immunoglobulin may be used as therapy in many diseases in different circumstances such as primary and secondary hypogammaglobulinemia, recurrent infections, polyneuropathies, cancer, after allogeneic transplantation in the presence of infections and/or GVHD. However, recent studies have broadened the possible uses of polyclonal immunoglobulin showing that it can stimulate certain sub-populations of T cells with effects on T cell proliferation, survival and function in situations of lymphopenia. These results present a novel and considerable impact of intravenous immunoglobulin (IVIg) treatment in situations of severe lymphopenia, a situation that can occur in cancer patients after chemo and radiotherapy treatments. In this review paper the established and experimental role of polyclonal immunoglobulin will be presented and discussed as well as the manufacturing processes involved in their production.

Keywords: IVIg; IVIg production; immune modulation; immunoglobulin; molecular mechanisms.

Similar articles

See all similar articles

Cited by 8 articles

See all "Cited by" articles

References

    1. Von Behring E. Untersuchungen ueber das Zustandekommen der Diphtherie-Immunitat bei Thieren (in Germany) Dtsch. Med. Wochenschr. 1890;16:1145–1148.
    1. Von Behring E., Kitasato S. Ueber das Zustandekommen der Diphtherie-Immunitat und der Tetanus-Immunitat bei Thieren (in Germany) Dtsch. Med. Wochenschr. 1890;16:1113–1114.
    1. Bruton O.C. Agammablobulinemia. Pediatrics. 1952;9:722–728. - PubMed
    1. Imbach P., Barandun S., Baumgartner C., Hirt A., Hofer F., Wagner H.P. High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv. Paediatr. Acta. 1981;36:81–86. - PubMed
    1. Radosevich M., Burnouf T. Intravenous immunoglobulin G: Trends in production methods, quality control and quality assurance. Vox Sang. 2010;98:12–28. doi: 10.1111/j.1423-0410.2009.01226.x. - DOI - PubMed

MeSH terms

Substances

Feedback